<DOC>
	<DOCNO>NCT00634569</DOCNO>
	<brief_summary>This multi-center , open-label study ass efficacy safety Flebogamma 5 % DIF pediatric population .</brief_summary>
	<brief_title>Safety Efficacy Study Flebogamma 5 % DIF IGIV Pediatric Subjects</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Deficiency Diseases</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<criteria>The subject 2 16 year old , either sex , belong ethnic group , minimum weight 10 kg ( weight base amount blood require test ) . The subject primary immunodeficiency disease , ( e.g. , common variable immunodeficiency , Xlinked autosomal form agammaglobulinemia , hyperIgM syndrome , WiskottAldrich Syndrome ) . The subject receive license IGIV replacement therapy dose change + 50 % mean dose mg/kg basis least 3 month study entry maintain trough level least 300 mg/dL baseline serum IgG level . Trough level IgG , dose IGIV , treatment interval last 2 consecutive routine IGIV treatment must document subject first infusion study administer . If subject adolescent female ( &gt; 12 year age ) become sexually active , must negative result pregnancy test ( HCGbased assay ) . The subject , old enough ( generally 6 year 16 ) sign inform Child Assent form subject 's parent legal guardian sign informed consent form , approve Institutional Review Board . Adult patient ( &gt; 17 year old ) . The subject history severe anaphylactic reaction blood bloodderived product . The subject know intolerant component product , sorbitol ( i.e. , intolerance fructose ) . The subject selective IgA deficiency demonstrable antibody IgA . The subject currently receive , receive , investigational agent within prior 3 month . The subject expose blood blood product derivative within last 6 month , commercially available IGIV . The adolescent subject pregnant nursing . The subject , screening , level great 2.5 time upper limit normal defined central laboratory pediatric patient follow : ALT AST LDH The subject severe preexist renal impairment ( define serum creatinine great 2 time ULN BUN great 2.5 time ULN laboratory , subject dialysis ) history acute renal failure . The subject history DVT thrombotic complication IGIV therapy . The subject suffers acute chronic medical condition ( e.g. , renal disease predispose condition renal disease , coronary artery disease , protein lose state ) , opinion Investigator , may interfere conduct study . The subject acquire medical condition lymphocytic leukemia , chronic recurrent neutropenia ( ANC less 1000 ) , AIDS know cause secondary immune deficiency , s/p hematopoetic stem cell transplantation . The subject receiving follow medication : Systemic corticosteroid ( longterm , i.e. , intermittent burst , daily , &gt; 1 mg prednisone equivalent/kg/day ) . Topical steroid ( ie nasal , inhaled asthma , and/or skin preparation eczema ) exclusionary . Immunosuppressive drug Immunomodulatory drug The subject noncontrolled arterial hypertension ( systolic blood pressure &gt; 160 mm Hg and/or diastolic blood pressure &gt; 100 mm Hg ) . The subject anemia ( hemoglobin &lt; 10 g/dL ) screening . The subject and/or parent/legal guardian subject unlikely adhere protocol requirement study likely uncooperative unable provide patient storage serum sample screen visit . ( Please note , pretreatment serum sample store 94° F ( 70º C ) possible future test absolutely require ) .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>CVID , XLA , hyper IgM syndrome , Wiskott-Aldrich Syndrome</keyword>
</DOC>